Disclosures

More documents

Recommendations

Info

Facts about Gram (-) NP • Ps.aeruginosa is the most common organism 24%, associated with a mortality of ~50% • Other emerging organisms resistant to Rx include: Acinetobacter spp. KPC, NDM-1, VIM’s, AMP-C Enterobacter, Klebsiella, E.coli etc’ , Stenotrophomonas sp. • Therapy options for these organisms: carbapenems (include. doripenem), colistinpolymyxin, amikacin, intra-tracheal amikacin, colistin,levofloxacin and aztreonam
Emergency department radiograph
Page 1 and 2: Disclosures Research support: Daiic
Page 3 and 4: Facts about nosocomial pneumonia (N
Page 5 and 6: Facts about staphylococcal NP • T
Page 7: MRSA prolongs ICU stay in VAP, desp
Page 12 and 13: STAPHYLOCOCCAL PNEUMONIA (SP) • P
Page 14 and 15: Virulence Factors • PSM (=phenol
Page 16 and 17: Hayward et al. Emerg Inf Dis. 2008;
Page 18 and 19: MRSA Load in the UK Male age standa
Page 20 and 21: Incidence of Nosocomial pneumonia c
Page 22 and 23: USA • S.aureus in 20% of cases of
Page 24 and 25: Vancomycin MIC creep 80 70 60 MIC
Page 26 and 27: Reduced vancomycin efficacy with hi
Page 28 and 29: Risk Factors for Multidrug-Resistan
Page 30 and 31: Mortality Rates Associated With Ina
Page 32 and 33: Mortality Risk with Increasing Dela
Page 34 and 35: Linezolid vs vancomycin for Gram-po
Page 36 and 37: Wunderink RG, et al. Chest. 2008;13
Page 38 and 39: Not such smart therapy • Vanco in
Page 40 and 41: RECENT STUDIES IN HAP/VAP Tigecycli
Page 42: Following his admission to the inte
Page 45 and 46: Characteristics of pneumonia caused
Page 47 and 48: Clinical features of PVL-associated
Page 49 and 50: 350% 300% PVL level reported to con
Page 53 and 54: Which antibiotics on MRSA? Vancomyc
Page 55 and 56: New therapeutic options for Resista
Page 57 and 58: • The real world utilization of t
Page 60:
Liang Beibei, et al. International
show all

Disclosures

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?